ONCOPIA THERAPEUTICS
ONCOPIA THERAPEUTICS
Industry:
Biotechnology Health Care
Founded:
2017-01-01
Address:
Malvern, Pennsylvania, United States
Country:
United States
Total Employee:
1+
Status:
Closed
Contact:
(610) 725-1500
Total Funding:
1.5 M USD
Similar Organizations
Biotech Holdings
Biotech Holdings is a provider of biotechnology service.
Cygnal Therapeutics
Cygnal Therapeutics is a biotechnology company
Emendo Biotherapeutics
Emendo Biotherapeutics is a biotechnology company
High Sierra Analytics
High Sierra Analytics is a provider of laboratory services intended to offer analytics and lab results to the agricultural industry.
ImmuCision Biotherapeutics
ImmuCision Biotherapeutics, LLC, is a privately owned biotechnology company.
Libra Therapeutics
Libra Therapeutics is a biotechnology company.
NE PLUS Corp.
NE PLUS Corp. is a provider of biotechnology services.
Personalbio
Personalbio is a Provider of gene sequencing and biotechnological services.
Powell Mansfield
Powell Mansfield is a provider of biotechnology service.
Primmune Therapeutics
Primmune Therapeutics is a Biotechnology company.
Pulmair Medical
Pulmair Medical is a provider of biotechnology services.
Pyramid Biosciences
Pyramid Biosciences is a provider of biotechnological services.
Rain Therapeutics
Rain Therapeutics is a operator of a clinical stage biotechnology company.
Renovo
Renovo Ltd. provides biotechnology services.
Target RWE
Target RWE is a provider of Biotechnology services.
TellBio
TellBio is a provider of biotechnology service.
Vibrant Composites
Vibrant Composites provides biotechnology research and development services.
WideCells Group
WideCells Group is a worldwide provider of stem cell services.
Xios Therapeutics
Xios Therapeutics is a biotechnology company .
Founder
More informations about "Oncopia Therapeutics"
Oncopia Therapeutics 2025 Company Profile: Valuation, Investors ...
Oncopia Therapeutics was founded in 2017. Where is Oncopia Therapeutics headquartered? Oncopia Therapeutics is headquartered in Malvern, PA. What industry is Oncopia …See details»
Oncopia Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Explore Oncopia Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 2 news, and 2 literature, Disease Domain:Neoplasms, Technology Platform:Proteolysis-targeting …See details»
Oncopia Therapeutics - Crunchbase Company Profile & Funding
Organization. Oncopia Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Oncopia Therapeutics is a provider …See details»
U-M Startup Oncopia Acquired by Roivant - UM - Innovation …
Feb 18, 2021 One of our biggest news stories happened as 2020 wound to a close when Roivant Pharma acquired University of Michigan (U-M) startup Oncopia Therapeutics, a …See details»
Oncopia Therapeutics, LLC Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Oncopia Therapeutics, LLC of Malvern, PA. Get the latest business insights from Dun & Bradstreet.See details»
Oncopia Therapeutics - Products, Competitors, Financials, …
Acknowledgements We are grateful for financial support from Oncopia Therapeutics, Proteovant Therapeutics and Roivant Sciences. This study is also supported, in part, by the Cancer …See details»
Oncopia Therapeutics, Llc in Malvern, Pennsylvania - EIN TaxId
Oncopia Therapeutics, Llc is a corporation in Malvern, Pennsylvania. The employer identification number (EIN) for Oncopia Therapeutics, Llc is 821993382. EIN for organizations is sometimes …See details»
Oncopia Therapeutics, Inc. · 10 Bank Street Suite 560
ONCOPIA THERAPEUTICS, INC. (DOS #5890919) is a Foreign Business Corporation in White Plains registered with the New York State Department of State (NYSDOS). The business …See details»
ONCOPIA THERAPEUTICS INC New York NY, 10036 - Company …
Free Business profile for ONCOPIA THERAPEUTICS INC at 151 W 42nd St, New York, NY, 10036-6631, US. ONCOPIA THERAPEUTICS INC specializes in: Commercial Physical and …See details»
Oncopia Therapeutics LLC - BioCentury Company Profiles - BCIQ
Feb 10, 2023 Oncopia Therapeutics LLC - BioCentury Company Profiles for the biopharma industrySee details»
Oncopia Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Oncopia Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 news, and 2 literature.See details»
Oncopia Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Dec 21, 2018: Seed Round - …See details»
Oncopia Therapeutics presents new CRBN ligands and its PROTACs
Apr 22, 2024 Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) has divulged protein cereblon (CRBN) ligands and its PROTACs reported to be useful for the treatment of cancer. …See details»
Oncopia Therapeutics - UM - Innovation Partnerships
Oncopia Therapeutics. BET and MDM2 degrader technologies. Launch: 2018. Subscribe to Our Newsletter . 1600 Huron Pkwy, Building 520, 2nd Floor Ann Arbor, MI 48109-2590 734-763 …See details»
ONCOPIA THERAPEUTICS,INC.: Drug pipelines, Patents, Clinical …
Jul 28, 2023 ONCOPIA THERAPEUTICS,INC. Last update 15 Jul 2023. Overview. Pipeline. Profit. Grant & Funding(NIH) Investment. Financing. Overview. Related. 0 Patents (Medical) …See details»
Roivant收购王少萌创立的Oncopia并完成2亿美元融资，开发蛋白 …
Dec 8, 2020 -2021年第一个有望进入临床研究的治疗性候选药物-计算机设计针对六个靶标的降解剂当前处于临床前开发中-收购Oncopia Therapeutics，并与密歇根大学的王少萌教授实验室进 …See details»
Oncopia Therapeutics divulges new CBP/P300 degraders
Mar 27, 2025 Patents from Oncopia Therapeutics Inc. (dba SK Life Science Labs) describe proteolysis targeting chimeric (PROTACs) compounds comprising a protein cereblon (CRBN) …See details»
Oncopia Therapeutics and University of Michigan report CRBN
Feb 7, 2024 Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) and the University of Michigan have prepared and tested new protein cereblon (CRBN) ligands expected to be …See details»
New Approach Allows Researchers To Hit “Undruggable” Cancer …
Apr 3, 2023 S.W., A.K., L.B. M.W., D.M., and J.S. are co-inventors on one or more of these patent applications and receive royalties from the University of Michigan. The University of …See details»
豪掷30亿美元布局AI制药，这家巨头如今也难抵医药寒冬？ - 知乎
Nov 28, 2022 2021年2月，波士顿的一家AI制药新锐Silicon Therapeutics以30亿美元身价被卖出，包括其推进到临床的两条药物管线。背后的大金主是生物制药公司Roivant Sciences。 ...See details»